This review evaluates current anti-hyperglycemic treatment in the context of AF, and discusses AF-related decision-making in comorbid DM (Cardiovascular Diabetology)
Diabetes News
Tag: atrial fibrillation
SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system
In a large pharmacovigilance database, AF was robustly and consistently reported more frequently for diabetes medications other than SGLT2i. This finding complements available evidence from trials supporting a protective role of SGLT2i against the occurrence of AF (Cardiovascular Diabetology)
Prognostic significance of diabetes mellitus in patients with atrial fibrillation
The presence of DM on top of AF was associated with substantially increased risk for all-cause or CV mortality, sudden cardiac death and excess morbidity (Cardiovascular Diabetology)
Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes?
sodium-glucose co-transporter 2 inhibitors (SGLT2i) empagliflozin has the capacity to restore mitochondrial function, ameliorate electrical and structural remodelling and prevent AF (Cardiovascular Diabetology)
Role of diabetes and insulin use in the risk of stroke and acute myocardial infarction in patients with atrial fibrillation
There is an incremental risk of ischemic stroke and MI from non-diabetics to non-insulin diabetics with the highest risk in insulin users. Protective effect of anticoagulation is attenuated with insulin use (American Heart Journal)
Effect of Diabetes and Glycemic Control on Ischemic Stroke Risk in AF Patients
Duration of diabetes is a more important predictor of ischemic stroke than glycemic control in patients who have diabetes and AF (JACC)
Risk of atrial fibrillation in diabetes mellitus: A nationwide cohort study
Diabetes is an independent risk factor for developing atrial fibrillation/flutter, most pronounced in young diabetes patients. Routine screening for atrial fibrillation/flutter in diabetes patients might be beneficial and have therapeutic implications, especially in younger diabetes patients (Preventative Cardiology)
Glycosmedia is also available as an App: